

Analytical report

Client:	Labocan B.V.	Contact:	Inge van Delft
Address:	Handelsweg 1a 5492 NL	City:	St. Oedenrode

Product:	Softgels CBD 4% Vitamin D3		
Date of sampling:	Unknown	Identification sample: (client)	Batch: 4V72D3 Exp.: 03/2022
Date of receipt sample:	22 June 2020	Identification sample: (Brightlabs)	BL- 2020-5950
Date start of analysis:	06 July 2020		

Cannabinoids

Analytical method: HPLC-UV

Compound	Results	Unit	Specification
CBDV	0.01	% (w/w)	Informative
CBDA	<LOQ	% (w/w)	Informative
CBGA	<LOQ	% (w/w)	Informative
CBG	0.11	% (w/w)	Informative
CBD	4.27	% (w/w)	Informative
THCV	<LOQ	% (w/w)	Informative
CBN	<LOQ	% (w/w)	Informative
DELTA9-THC	<LOQ	% (w/w)	Informative
DELTA8-THC	<LOQ	% (w/w)	Informative
CBC	<LOQ	% (w/w)	Informative
THCA	<LOQ	% (w/w)	Informative

Limit of Quantification (LOQ): 0.005 % w/w

Vitamin D3

Analytical method: HPLC-UV

Compound	Results	Unit	Specification
Vitamin D3	0.191	µg/mg oil phase	Informative

Remarks:

CoA-2020-5950A replaces CoA-2020-5950.
Each Softgel contains 160mg oil according Labocan B.V.. The Vitamin D3 result complies therefore with 30.6 mg per capsule.



Nina Firl
Project leader